Fibrocell Science is an autologous cell and gene therapy company, focusing on discovering and developing therapies for diseases affecting the skin, connective tissues and joints. The Company’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Type
Public
HQ
Exton, US
Founded
1995
Size (employees)
23 (est)-55%
Fibrocell Science was founded in 1995 and is headquartered in Exton, US
Report incorrect company information

Key People/Management at Fibrocell Science

John Maslowski

John Maslowski

President and Chief Executive Officer
Pamela Swiggard

Pamela Swiggard

Vice President of Regulatory Affairs and Quality Assurance
Sean Buckley

Sean Buckley

Vice President of Business Administration and Corporate Secretary

Fibrocell Science Office Locations

Fibrocell Science has an office in Exton
Exton, US (HQ)
405 Eagleview Boulevard
Show all (1)
Report incorrect company information

Fibrocell Science Financials and Metrics

Fibrocell Science Financials

Fibrocell Science's revenue was reported to be $355 k in FY, 2016 which is a 27.8% decrease from the previous period.
USD

Net income (FY, 2017)

(16.2 m)

EBIT (FY, 2017)

(19 m)

Market capitalization (23-Apr-2018)

9.1 m

Cash (31-Dec-2017)

17.4 m
Fibrocell Science's current market capitalization is $9.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

200 k180 k492 k355 k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

722 k697 k

Gross profit

(230 k)(342 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

194 k137 k79 k16 k87 k215 k

Cost of goods sold

1.9 m793 k547 k512 k147 k162 k204 k18 k392 k287 k

Gross profit

47 k(25 k)(125 k)(2 k)(305 k)(72 k)

Gross profit Margin, %

24%(18%)(158%)(12%)(351%)(33%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60 m37.5 m29.3 m17.5 m17.4 m

Accounts Receivable

Inventories

1.2 m1.3 m1.2 m

Current Assets

61.9 m39.3 m31 m18 m17.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

16.9 m54 m49.5 m44.2 m33.3 m26.9 m36.9 m13.1 m8.2 m21.3 m20.6 m15.9 m

Inventories

574 k506 k476 k610 k544 k484 k566 k475 k109 k

Current Assets

19.2 m55.5 m50.7 m45.3 m34.9 m28.1 m38 m14.6 m8.9 m21.7 m21.1 m16.4 m

Total Assets

26.3 m62.4 m57.4 m51.9 m41.2 m34.1 m43.9 m20.2 m10.5 m23.2 m22.7 m18 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.6 m)(25.7 m)(34.5 m)(15.3 m)(16.2 m)

Depreciation and Amortization

863 k883 k767 k564 k384 k

Inventories

(120 k)26 k35 k126 k

Accounts Payable

2 m(1.8 m)(114 k)(139 k)69 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(25 m)(14 m)(16.3 m)(22.3 m)(8.5 m)(15.3 m)(1.5 m)(1.4 m)(8.1 m)(2.3 m)(5 m)(19 m)

Depreciation and Amortization

693 k222 k452 k673 k140 k346 k91 k184 k

Inventories

(97 k)91 k121 k(13 k)27 k87 k566 k475 k

Accounts Payable

248 k(2.1 m)(1.6 m)(1.9 m)774 k833 k2.6 m893 k553 k361 k(55 k)192 k
USDY, 2017

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information